Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Pfizer and Janssen back online video resource for Alzheimer's disease

The companies, which are collaborating on Alzheimer's candidate bapineuzumab, have partnered with health content provider The Visual MD

Pfizer Janssen Alzheimer's disease awareness video

Pfizer and Janssen are funding a new online video resource for patients suffering from Alzheimer's disease.

The pharma companies' Alzheimer's Disease Health Center is hosted by health information site The Visual MD and features a 'video booklet' explaining how the neurodegenerative disease develops and can be detected.

The video was backed by Pfizer and Janssen's collaboration the Alzheimer's Immunotherapy Program (AIP), which focuses on the research, development and commercialisation of neurodegenerative products.

"[The video] project provides a rich, visual experience to learn and understand more about the causes, impact and risk factors of Alzheimer's disease," explained George Migias, senior director, commercial development, AIP - bapineuzumab.

"We hope that sharing key information about Alzheimer's disease in this cutting-edge format and forum will help people who are affected by this disease."

AIP's lead product is the humanised monoclonal antibody bapineuzumab. This is currently in phase III trials for mild to moderate Alzheimer's disease but these faltered after some cases emerged in 2008 of vasogenic edema  - a brain swelling condition.

US regulators subsequently tightened trial guidelines for drugs like bapineuzumab that alter amyloid, a protein that accumulates in the brains of Alzheimer's patients, making it harder to recruit patients for clinical trials.

These guidelines were relaxed in July this year, potentially kick-starting Pfizer and Janssen's research. The companies need 1,300 participants in their phase III trial programme, but having halted recruitment for this they have yet to re-start it.

Earlier this year in May, Janssen said it planned to submit bapineuzumab to US regulators for approval in 2012 or 2013.

23rd November 2011

From: Marketing

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics